A company and its former subsidiary have settled with the US Federal Trade Commission, which said the companies' advertising claims regarding their genetically tailored nutritional supplements and skincare products were deceptive.
Registering provides access to this and other free content.
Already have an account?Login Now.
The New York Times' George Johnson muses on cancer's roots in multicellularity.
The San Diego Union Tribune wonders whether Medicare is ready for personalized medicine.
Jun Wang, the chief executive of BGI, has stepped down.
In PNAS this week: human T cell editing with CRISPR, retrotransposons acting as insulators, and more.